Русский
The Kazakh Health Ministry has issued a registration certificate to Russia’s Promomed biopharmaceutical company, for the Tirzepatide medicinal product, also known as Tirzetta, used in the treatment of type II diabetes mellitus and obesity.
Promomed said that “in the near future, Tirzetta will appear on the Kazakh market. Our drug will become the first officially available drug with this active substance in the country.”
The effect of the drug provides a new quality of body weight reduction—a marked decrease in the volume of adipose tissue while carefully preserving the muscular corset and forming a physiologically correct “beautiful” silhouette. Tirzepatide—the active ingredient of the drug Tirzetta®—is a new class of incretins that activates two receptors regulating metabolism at once—GLP-1 and GIP. Their combined effect provides greater selectivity of the mechanism of regulation of metabolism, levels of insulin and glucose in the blood, and the metabolic rate in specific tissues. As a result, body weight decreases mainly due to increased metabolism of adipose tissue reserves.
The company added that there is demand in Kazakhstan for the treatment of these diabetes and other problems associated with obesity diseases. According to WHO data for 2024, 56% of Kazakhstan’s adult population are overweight, higher than the global average of 45%.
The Tirzetta brand is the flagship in Promomed’s portfolio. According to DSM Group, it has become the best-selling drug in Russian pharmacies in 2026, with its share in sales of all tirzepatide-based drugs at 70% in the first half of the year.
The Promomed Group has already established Promomed-Pharma LLP in Kazakhstan to promote its products in international markets. Alexander Yefremov, the company’s general director, said that export revenues will amount to about 5% of Promomed’s total income by the end of 2026.
The Promomed Group held an IPO in July 2024, with the placement attracting about ₽6 billion (US$71 million). That income has assisted in getting the company into other markets.
